NCT06033261: An ongoing trial by ModernaTX, Inc.
This trial is ongoing. It must report results 4 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06033261 |
|---|---|
| Title | A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 6, 2023 |
| Completion date | April 25, 2025 |
| Required reporting date | April 25, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |